Adaptive Biotechnologies Corporation (ADPT) Stock
ADPT Key Statistics
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
CEO: Chad Robins. Company website
ADPT — Frequently Asked Questions
What is the ADPT stock price today?
Adaptive Biotechnologies Corporation (ADPT) trades at $29.94, up 1.98% on the day, as of Nov 12, 2026 09:30 UTC.
What is Adaptive Biotechnologies Corporation's market cap?
Adaptive Biotechnologies Corporation has a market capitalisation of $4.78B, calculated from the live ADPT share price and shares outstanding.
What is the P/E ratio of ADPT?
ADPT has no meaningful price-to-earnings ratio: Adaptive Biotechnologies Corporation lost $0.46 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Adaptive Biotechnologies Corporation make?
Adaptive Biotechnologies Corporation generated revenue of $298.01M over the trailing twelve months, which puts the stock at 16.03 times sales.
What is the 52-week range for ADPT?
ADPT has traded between $12.00 and $32.21 over the past 52 weeks, and the last price is 7.0% below that high.
Is Adaptive Biotechnologies Corporation profitable?
No. Adaptive Biotechnologies Corporation is loss-making, with a net margin of -23.66% over the trailing twelve months.
What is the analyst price target for ADPT?
Wall Street analysts rate ADPT Buy, with an average price target of $31.58, 5.5% above the current price.
What sector is Adaptive Biotechnologies Corporation in?
Adaptive Biotechnologies Corporation is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Adaptive Biotechnologies Corporation?
Chad Robins is the chief executive of Adaptive Biotechnologies Corporation, which employs 624 people.
Where can I track ADPT in real time?
QFI Terminal shows ADPT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ADPT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ADPT in Terminal See plans